Jynarque 90MG/30MG
Ended Awarded
- Contract number
- 36C24524N0081
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $12,196
Award facts
- Contract value 100% obligated
- $12,195.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
Otsuka America Pharmaceutical Inc., a Maryland-based specialty pharmaceutical manufacturer, was awarded a firm fixed price delivery order valued at $12,195.72 by Veterans Integrated Service Network 5 (VISN 5) on October 4, 2023, with an ultimate completion date of October 6, 2023. The contract calls for the delivery of Jynarque (tolvaptan) in 90mg/30mg dosages to support the Department of Veterans Affairs' healthcare operations in Pittsburgh, Pennsylvania. This delivery order operates under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and carries no set-aside designation, reflecting the vendor's status as an established large pharmaceutical manufacturer serving the VA system.
This award is part of Otsuka America Pharmaceutical Inc.'s broader engagement with the VA, which includes an $83.3 million Blanket Purchase Agreement for Jynarque and a $396 million Federal Supply Schedule contract for pharmaceuticals and hematology products. The delivery order supports the VA's mission of providing specialized pharmaceutical treatments to veterans, with Jynarque used to treat autosomal dominant polycystic kidney disease and hyponatremia. The company has consistently delivered similar medication orders across multiple VA Integrated Service Networks, demonstrating its capability to supply critical pharmaceutical treatments efficiently to the federal healthcare system.
Quick answers
Who was awarded contract 36C24524N0081?
36C24524N0081 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on October 4, 2023.
How much is contract 36C24524N0081 worth?
The government has obligated $12,196 on 36C24524N0081.
Is contract 36C24524N0081 an order under another contract?
Yes. 36C24524N0081 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24524N0081 competed?
The extent of competition for 36C24524N0081 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award